

At the request of Kris McCalister

**PROPOSED AMENDMENTS TO
SENATE BILL 1057**

1 On page 1 of the printed bill, line 8, after “475B.430,” insert “475B.520,”.

2 On page 15, after line 39, insert:

3

4 **“ADVISORY COMMITTEE ON MEDICAL MARIJUANA**

5

6 **“SECTION 36c.** ORS 475B.520 is amended to read:

7 “475B.520. (1) There is established within the Oregon Health Authority
8 the Advisory Committee on Medical Marijuana, consisting of 11 members
9 appointed by the Director of the Oregon Health Authority.

10 “(2) The director shall appoint members of the committee from persons
11 who are knowledgeable about marijuana or who are registered with the au-
12 thority under ORS 475B.400 to 475B.525 and who are advocates for the med-
13 ical use of marijuana, provided that:

14 **“(a)** A majority of the members of the committee are registered with the
15 authority under ORS [*475B.400 to 475B.525 and are advocates for the medical*
16 *use of marijuana.*] **475B.415; and**

17 **“(b) At least three members of the committee are registered under**
18 **ORS 475B.420, 475B.435 or 475B.450.**

19 “(3) The committee shall:

20 **“(a)** Advise the director on the administrative aspects of ORS 475B.400
21 to 475B.525, including rules and fees adopted, and proposed for adoption,

1 under ORS 475B.400 to 475B.525[.];

2 **“(b) Serve as a coordinating body between the Oregon Health Au-**
3 **thority and the Oregon Liquor Control Commission on the adminis-**
4 **tration of ORS 475B.010 to 475B.395 and 475B.400 to 475B.525 with**
5 **respect to registry identification cardholders and designated primary**
6 **caregivers;**

7 **“(c) Identify and evaluate potential factors that could prevent a**
8 **registry identification cardholder from accessing usable marijuana,**
9 **medical cannabinoid products, cannabinoid concentrates and**
10 **cannabinoid extracts for medical use;**

11 **“(d) Make recommendations to the authority on the implementa-**
12 **tion of processes and regulations that would ensure that registry**
13 **identification cardholders have access to usable marijuana, medical**
14 **cannabinoid products, cannabinoid concentrates and cannabinoid ex-**
15 **tracts for medical use;**

16 **“(e) Make recommendations to the authority on the public and**
17 **private research of the medical properties of cannabis and how to fa-**
18 **cilitate the public and private research of cannabis;**

19 **“(f) Compile information regarding:**

20 **“(A) The availability of different strains of usable marijuana and**
21 **different types of medical cannabinoid products, cannabinoid concen-**
22 **trates and cannabinoid extracts;**

23 **“(B) The levels of tetrahydrocannabinol present in different strains**
24 **of usable marijuana and different types of medical cannabinoid pro-**
25 **ducts, cannabinoid concentrates and cannabinoid extracts;**

26 **“(C) Whether those levels of tetrahydrocannabinol are intoxicating**
27 **and the availability of strains of usable marijuana and types of medical**
28 **cannabinoid products, cannabinoid concentrates and cannabinoid ex-**
29 **tracts that are not intoxicating;**

30 **“(D) For each type of debilitating medical condition, the strains of**

1 usable marijuana and the types of medical cannabinoid products,
2 cannabinoid concentrates and cannabinoid extracts that most effec-
3 tively treat that debilitating medical condition;

4 “(E) For selected medical conditions that are not debilitating med-
5 ical conditions, the strains of usable marijuana and the types of med-
6 ical cannabinoid products, cannabinoid concentrates and cannabinoid
7 extracts that most effectively treat that medical condition; and

8 “(F) Those medical conditions that are not debilitating medical
9 conditions that should be included as debilitating medical conditions,
10 and whether the inclusion of the conditions should be by administra-
11 tive or legislative action; and

12 “(g) Monitor and study federal laws and regulations regarding
13 marijuana, the administration of those laws and regulations by the
14 federal government and the impact of that administration on ORS
15 475B.400 to 475B.525.

16 *[(4) The committee shall meet at least four times per year, at times and*
17 *places specified by the director.]*

18 “(4) A majority of the members of the committee constitutes a
19 quorum for the transaction of business.

20 “(5) Official action by the committee requires the approval of a
21 majority of the members of the committee.

22 “(6) The committee shall elect one of its members to serve as
23 chairperson.

24 “(7) The committee shall meet at times and places specified by the
25 call of the chairperson or of a majority of the members of the com-
26 mittee.

27 “(8) The term of office of each member of the committee is four
28 years, but a member serves at the pleasure of the Governor. Before
29 the expiration of the term of a member, the Governor shall appoint a
30 successor whose term begins July 1 next following. A member is eli-

1 **gible for reappointment, but may not serve consecutive terms. If there**
2 **is a vacancy for any cause, the Governor shall make an appointment**
3 **to become immediately effective for the unexpired term.**

4 **“(9) Members of the committee are not entitled to compensation.**

5 **“[(5)] (10) The authority shall provide staff support to the committee.**

6 **“[(6)] (11) All agencies of state government, as defined in ORS 174.111,**
7 **are directed to assist the committee in the performance of its duties and, to**
8 **the extent permitted by laws relating to confidentiality, to furnish informa-**
9 **tion and advice that the members of the committee consider necessary to**
10 **perform their duties.**

11 **“SECTION 36d. Notwithstanding the term of office specified by ORS**
12 **475B.520, as amended by section 36c of this 2017 Act, of the members**
13 **appointed to the Advisory Committee on Medical Marijuana after the**
14 **effective date of this 2017 Act:**

15 **“(1) Two shall serve for terms ending June 30, 2019;**

16 **“(2) Two shall serve for terms ending June 30, 2020;**

17 **“(3) Two shall serve for terms ending June 30, 2021; and**

18 **“(4) Three shall serve for terms ending June 30, 2022.”.**

19
